Treatment of functional dyspepsia

Current Treatment Options in Gastroenterology

Volumn 8, Issue 4, 2005, Pages 325-336

  Halder, Smita L S ^a   Talley, Nicholas J ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTACID AGENT; ANTIDEPRESSANT AGENT; BISMUTH SALT; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CIMETIDINE; CISAPRIDE; CLOMIPRAMINE; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ERYTHROMYCIN; FAMOTIDINE; FLUOXETINE; HERBACEOUS AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; ITOPRIDE; LANSOPRAZOLE; METOCLOPRAMIDE; MIANSERIN; OMEPRAZOLE; OPIATE AGONIST; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE; SEROTONIN AGONIST; STOMACH SECRETION INHIBITOR; SUCRALFATE; SULPIRIDE; UNINDEXED DRUG;

BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DROWSINESS; DYSPEPSIA; EPIGASTRIC PAIN; ERADICATION THERAPY; FUNCTIONAL DISEASE; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; HYPNOSIS; MEDICAL DECISION MAKING; META ANALYSIS; PATHOPHYSIOLOGY; PSYCHODYNAMICS; PSYCHOTHERAPY; REVIEW; SATIETY; STOMACH ACID SECRETION; TARDIVE DYSKINESIA;

EID: 24044452144     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-005-0026-8     Document Type: Review

References (58)

1. Locke GR, 3rd: The epidemiology of functional gastrointestinal disorders in North America. Gastroenterol Clin North Am 1996, 25:1-19.
2. Nyren O, Lindberg G, Lindstrom E, et al.: Economic costs of functional dyspepsia. Pharmacoeconomics 1992, 1:312-324.
3. Moayyedi P, Mason J: Clinical and economic consequences of dyspepsia in the community. Gut 2002, 50(Suppl 4):iv10-iv12.
4. Stanghellini V, Tosetti C, Paternic A, et al.: Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996, 110:1036-1042.
5. Tack J, Caenepeel P, Fischler B, et al.: Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001, 121:526-535.
6. Samsom M, Verhagen MA, vanBerge Henegouwen GP, et al.: Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999, 116:515-520.
7. Holtmann G, Siffert W, Haag S, et al.: G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004, 126:971-979.
8. Talley NJ, Silverstein MD, Agreus L, et al.: AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998, 114:582-595.
9. Talley NJ, Quan C: Review article: Helicobacter pylori and nonulcer dyspepsia. Aliment Pharmacol Ther 2002, 16(Suppl 1):58-65.
10. Moayyedi P, Soo S, Deeks J, et al.: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005, 1:CD002096.
11. Chiba N, Van Zanten SJ, Sinclair P, et al.: Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial.[see comment]. BMJ 2002, 324:1012-1016.
12. Farkkila M, Sarna S, Valtonen V, et al.: Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. Scandinavian Journal of Gastroenterology 2004, 39:327-335.
13. Moayyedi P, Delaney BC, Vakil N, et al.: The efficacy of proton pump inhibitors in nonulcer dyspepsia: A systematic review and economic analysis. Gastroenterology 2004, 127:1329-1337.
14. Moayyedi P, Soo S, Deeks J, et al.: Systematic review: Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther 2003, 17:1215-1227.
15. Tatsuta M, Iishi H, Nakaizumi A, et al.: Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharmacol Ther 1992, 6:221-228.
16. Corinaldesi R, Stanghellini V, Raiti C, et al.: Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987, 28:300-305.
17. Kellow JE, Cowan H, Shuter B, et al.: Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther 1995, 9:153-160.
18. Tack J, Bisschops R, Sarnelli G: Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004, 127(4):1239-1255.
19. Gotthard R, Bodemar G, Brodin U, et al.: Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988, 23:7-18.
20. Nyren O, Adami HO, Bates S, et al.: Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 1986, 314:339-343.
21. Moayyedi P, Soo S, Deeks J, et al.: Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2004:CD001960.
22. Haug TT, Svebak S, Wilhelmsen I, et al.: Psychological factors and somatic symptoms in functional dyspepsia. A comparison with duodenal ulcer and healthy controls. J Psychosom Res 1994, 38:281-291.
23. Talley NJ, Fung LH, Gilligan IJ, et al.: Association of anxiety, neuroticism, and depression with dyspepsia of unknown cause. A case-control study. Gastroenterology 1986, 90:886-892.
24. Haug TT, Svebak S, Hausken T, et al.: Low vagal activity as mediating mechanism for the relationship between personality factors and gastric symptoms in functional dyspepsia. Psychosom Med 1994, 56:181-186.
25. Lorena SL, Tinois E, Brunetto SQ, et al.: Gastric emptying and intragastric distribution of a solid meal in functional dyspepsia: influence of gender and anxiety. J Clin Gastroenterol 2004, 38:230-236.
26. Camilleri M, Malagelada JR, Kao PC, et al.: Gastric and autonomic responses to stress in functional dyspepsia. Dig Dis Sci 1986, 31:1169-1177.
27. Soo S, Moayyedi P, Deeks J, et al.: Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2004:CD002301.
28. Haug TT, Wilhelmsen I, Svebak S, et al.: Psychotherapy in functional dyspepsia. J Psychosom Res 1994, 38:735-744.
29. Hamilton J, Guthrie E, Creed F, et al.: A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000, 119:661-669.
30. Calvert EL, Houghton LA, Cooper P, et al.: Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002, 123:1778-1785.
31. Bates S, Sjoden PO, Nyren O: Behavioral treatment of non-ulcer dyspepsia. Scand J Behav Ther 1988, 17:155-165.
32. Jackson JL, O'Malley PG, Tomkins G, et al.: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000, 108:65-72.
33. Loldrup D, Langemark M, Hansen HJ, et al.: Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. Psychopharmacology (Berl) 1989, 99:1-7.
34. Mertz H, Fass R, Kodner A, et al.: Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998, 93(2):160-165.
35. Tack J, Broekaert D, Coulie B, et al.: Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003, 17:603-608.
36. Tindle HA, Davis RB, Phillips RS, et al.: Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 2005, 11:42-49.
37. Holtmann G, Adam B, Haag S, et al.: Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. Aliment Pharmacol Ther 2003, 18:1099-1105.
38. Thompson Coon J, Ernst E: Herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther 2002, 16:1689-1699.
39. Melzer J, Rosch W, Reichling J, et al.: Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004, 20:1279-1287.
40. Tack J, Piessevaux H, Coulie B, et al.: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998, 115:1346-1352.
41. Mertz H, Fullerton S, Naliboff B, et al.: Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998, 42:814-822.
42. Tack J, Coulie B, Wilmer A, et al.: Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000, 46:468-473.
43. Tack J, Caenepeel P, Corsetti M, et al.: Role of tension receptors in dyspeptic patients with hypersensitivity to gastric distention. Gastroenterology 2004, 127:1058-1066.
44. Camilleri M, Mayer EA, Drossman DA, et al.: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999, 13:1149-1159.
45. Talley NJ, Van Zanten SV, Saez LF, et al.: A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001, 15:525-537.
46. Delvaux M, Louvel D, Lagier E, et al.: The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999, 116:38-45.
47. Read NW, Abitbol JL, Bardhan KD, et al.: Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997, 41:664-668.
48. Fraitag B, Homerin M, Hecketsweiler P: Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia. Dig Dis Sci 1994, 39:1072-1077.
49. Delgado-Aros S, Chial HJ, Cremonini F, et al.: Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003, 18:507-514.
50. Mansi C, Borro P, Giacomini M, et al.: Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000, 14:561-569.
51. Distrutti E, Fiorucci S, Hauer SK, et al.: Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia. Aliment Pharmacol Ther 2002, 16:613-622.
52. Mearin F, Rodrigo L, Perez-Mota A, et al.: Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol 2004, 2:301-308.
53. Tsubouchi T, Saito T, Mizutani F, et al.: Stimulatory action of itopride hydrochloride on colonic motor activity in vitro and in vivo. J Pharmacol Exp Ther 2003, 306:787-793. Epub 2003 Apr 30.
54. Holtmann G, Schnittker J, Boos G, et al.: A randomized, double-blind, placebo-controlled dose finding study of Itopride for the treatment of patients with funcitonal dyspepsia. Gastroenterology 2004, 126:A-100.
55. Feinle C, Grundy D, Otto B, et al.: Relationship between increasing duodenal lipid doses, gastric perception, and plasma hormone levels in humans. Am J Physiol Regul Integr Comp Physiol 2000, 278:R1217-R1223.
56. Moran TH, Kinzig KP: Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol Gastrointest Liver Physiol 2004, 286:G183-G188.
57. Feinle C, Meier O, Otto B, et al.: Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001, 48:347-355.
58. Varga G: Dexloxiglumide Rotta Research Lab. Curr Opin Investig Drugs 2002, 3:621-626.